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Abstract: Cushing’s syndrome is a rare disorder resulting from prolonged exposure to excess glu-
cocorticoids. Early diagnosis and treatment of Cushing’s syndrome is associated with a decrease in 
morbidity and mortality. Clinical presentation can be highly variable, and establishing the diagnosis 
can often be difficult. Surgery (resection of the pituitary or ectopic source of adrenocorticotropic 
hormone, or unilateral or bilateral adrenalectomy) remains the optimal treatment in all forms of 
Cushing’s syndrome, but may not always lead to remission. Medical therapy (steroidogenesis 
inhibitors, agents that decrease adrenocorticotropic hormone levels or glucocorticoid receptor 
antagonists) and pituitary radiotherapy may be needed as an adjunct. A multidisciplinary approach, 
long-term follow-up, and treatment modalities customized to each individual are essential for 
optimal control of hypercortisolemia and management of comorbidities.
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Introduction
Cushing’s syndrome is a rare disorder caused by prolonged exposure to excess 
glucocorticoids. The clinical presentation is highly variable. While the diagnosis can 
be straightforward in florid cases, establishing the diagnosis can be challenging in 
cases with mild hypercortisolism and subtle clinical features, especially given the 
overlap in symptoms in individuals with and without the syndrome.1 Here, we discuss 
the epidemiology, diagnosis, and advances in management of endogenous Cushing’s 
syndrome.
Epidemiology and prognosis
Administration of supraphysiologic doses of glucocorticoids is the most common 
cause of Cushing’s syndrome (exogenous or iatrogenic Cushing’s syndrome).2 As 
glucocorticoids are used to treat inflammatory, autoimmune, and neoplastic disorders, 
a detailed medication history is essential. Although the oral route is most commonly 
associated with iatrogenic Cushing’s syndrome, any mode of delivery, including 
inhaled, topical, or injectable glucocorticoids, should be sought.
Endogenous Cushing’s syndrome is rare, with an incidence of 0.7–2.4 per million 
population per year.1,3,4 A population-based study from Denmark reported a diagnosis 
of Cushing’s syndrome in 166 patients over an 11-year period (1985–1995), yielding 
an incidence of two cases per million inhabitants per year.3 Of the 139 patients with 
nonmalignant disease, 23 (16.5%) died during follow-up (median 8 years), yielding 
a standard mortality ratio of 3.7 (95% confidence interval 2.3–5.3), with the highest 
mortality during the first year after initial presentation. Eight deaths occurred before 
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initiation of treatment. Causes of death included suicide 
(n=1), cardiac rupture (n=1), stroke (n=1), and severe infec-
tions (n=3; peritonitis, septicemia, and pneumonia). The 
cause of death could not be ascertained in two patients. 
A similar study from Spain reported 49 cases of Cushing’s 
syndrome over 18 years, yielding an incidence of 2.4 cases 
per million inhabitants per year, with a standard mortality 
ratio of 3.8.4 Although the mortality risk decreases with 
remission of hypercortisolism,5 it is not equivalent to that 
of the general population. Several studies have shown that 
increased morbidity, especially related to cardiovascular 
disease, persists for several years after biochemical remis-
sion.6–9 Furthermore, varying criteria for remission of hyper-
cortisolemia across studies make it difficult to interpret these 
outcome measures accurately.
Although population-based studies demonstrate a low 
incidence of endogenous Cushing’s syndrome, more evalu-
ations of patients with uncontrolled diabetes mellitus or 
hypertension suggest that this may be an underestimation.10–13 
Leibowitz et al screened 90 obese subjects with uncontrolled 
diabetes mellitus (hemoglobin A
1c
 .9%), and found three 
(3.3%) to have Cushing’s syndrome.10 Similarly, Catargi et al 
diagnosed Cushing’s syndrome in four (2%) of 200 obese 
subjects with uncontrolled diabetes mellitus.11 However, 
this reported prevalence of 2%–5% was not confirmed in 
other studies.14–17 Also, an evaluation of 369 overweight and 
obese subjects with at least two other features of Cushing’s 
syndrome did not identify any with Cushing’s syndrome, but 
84 subjects had at least one abnormal screening test result.18 
Widespread screening for Cushing’s syndrome in overweight 
individuals or patients with type 2 diabetes mellitus is there-
fore not recommended.18,19 Instead, a case-finding approach 
in patients with other features of Cushing’s syndrome or 
uncontrolled diabetes or hypertension despite appropriate 
treatment may be indicated.19
Currently, extensive use of computed tomography (CT) 
and magnetic resonance imaging (MRI) scans has led to an 
increasing number of incidentally found adrenal masses. The 
prevalence of these adrenal “incidentalomas” increases from 
0.2% to 7% with increasing age.20–22 “Subclinical” or subtle 
Cushing’s syndrome has been reported in 5%–10% of these 
patients, who represent a population in which Cushing’s 
syndrome is more common.22,23
Classification of Cushing’s syndrome
Traditionally, endogenous Cushing’s syndrome is classified as 
adrenocorticotropic hormone (ACTH)-dependent or ACTH-
independent. ACTH-dependent Cushing’s syndrome accounts 
for 80%–85% of cases. Of these, 75%–80% are due to ACTH 
production from a pituitary adenoma (Cushing’s disease 
[CD]), 15%–20% are due to ACTH production from nonpitu-
itary tumors (ectopic ACTH syndrome [EAS]) and ,1% are 
caused by corticotropin-releasing hormone (CRH)-producing 
tumors.1,23 Most pituitary tumors are sporadic, resulting from 
monoclonal expansion of a single mutated cell. Rarely, they 
may occur as part of a genetic syndrome, the most common 
being multiple endocrine neoplasia type 1 and familial iso-
lated pituitary adenomas. Ectopic ACTH secretion most often 
derives from small-cell carcinoma of the lung or pulmonary 
carcinoid tumor. Other causes include pancreatic neuroendo-
crine tumors (NETs), thymic NETs, gastrinomas, medullary 
thyroid cancer, and pheochromocytoma.24
ACTH-independent Cushing’s syndrome accounts for 
15%–20% of endogenous Cushing’s syndrome in adults; 90% 
are unilateral adrenal tumors. Of these, adenomas are the cause 
in ∼80% of the cases, while the others are adrenocortical car-
cinoma.25 Rare adrenal causes of Cushing’s syndrome include 
macronodular adrenal hyperplasia, primary pigmented nodu-
lar adrenal disease (sporadic or as part of Carney’s complex) 
and McCune–Albright syndrome. In a recent study, Louiset 
et al described intra-adrenal production of ACTH and para-
crine regulation of cortisol secretion in 30 cases of bilateral 
macronodular adrenal hyperplasia.26 Proopiomelanocortin 
messenger ribonucleic acid expression was detected in all 
hyperplastic tissue samples and ACTH was detected in ste-
roidogenic cell clusters throughout adrenal tissue specimens. 
ACTH levels were also found to be higher in adrenal venous 
samples of two patients compared to the periphery.26 These 
findings bring into question the traditional classification of 
“ACTH-independent Cushing’s syndrome”.27
In childhood and adolescence, as in adults, exogenous 
glucocorticoids are the most common cause of Cushing’s 
syndrome. The causes of endogenous Cushing’s syndrome in 
children are similar to those in adults, with some differences. 
Cushing’s syndrome in infancy is commonly associated 
with McCune–Albright syndrome, adrenocortical tumors 
are usually the cause in children less than 5–7 years of age, 
CD is the commonest cause after 7 years of age, and EAS 
is extremely rare.28
Clinical features of  
Cushing’s syndrome
The clinical presentation of Cushing’s syndrome is variable 
(Table 1). It is influenced by age and sex and the severity and 
duration of the disease.1,24,28–31 No single sign or symptom 
is pathognomonic.
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While weight gain is the most common sign of Cushing’s 
syndrome, it is also extremely common in patients without 
the syndrome.18 Moreover, an underlying malignancy or 
paraneoplastic wasting syndrome can mask the weight gain 
associated with hypercortisolism. As may be concluded from 
Table 1, establishing a diagnosis based on clinical features 
alone can be difficult. Some of the features that are thought 
to distinguish Cushing’s syndrome more reliably from simple 
obesity include proximal muscle weakness, easy bruising, 
and violaceous striae greater than 1 cm wide. Decreased 
linear growth along with progressive weight gain is one of 
the hallmarks of pediatric Cushing’s syndrome.32 Detailed 
description of differences in presentation between pediatric 
and adult Cushing’s syndrome is beyond the scope of this 
review.28,33,34
The clinical presentation of Cushing’s syndrome can vary 
by sex. Men with CD are more likely to present at a younger 
age with more florid clinical features. Violaceous striae, 
muscle weakness and atrophy, osteoporosis, and  kidney 
stones are much more common.29 Gonadal dysfunction is 
common in both men and women, presenting as decreased 
libido, infertility, menstrual irregularity or amenorrhea in 
women, and erectile dysfunction in men. While CD has a 
female preponderance (female:male ratio 3–4:1), EAS is 
equally common in both sexes among the adult population.24 
Unlike adults, pediatric CD is characterized by significant 
male preponderance in the prepubertal years. With increasing 
age, the sex distribution of CD equalizes toward puberty, with 
a trend toward female preponderance in adulthood.28,33,34
Classically, patients with ectopic Cushing’s have severe 
hypercortisolemia associated with a rapid onset of symptoms 
and a florid presentation, hypokalemia, and severe or oppor-
tunistic infections.24,35,36 However, these features reflect the 
severity of hypercortisolism, and can be seen in patients with 
CD. By contrast, the clinical presentation of many ACTH-
secreting carcinoid tumors may be indistinguishable from that 
of CD, reflecting less extreme hypercortisolism.24,37
Decreased bone mineral density, osteoporosis, and frac-
tures are present in 50%–80% of patients with Cushing’s 
syndrome. After cure, bone mineral density improves, but 
additional specific treatment for fractures and related pain 
may be needed. Bone loss can be more severe in primary 
adrenal disease compared to CD. This may be related to a 
protective effect of the higher adrenal androgen levels in 
CD.38,39 However, these findings have not been reproduced 
in other studies, and the significance of disease etiology in 
bone loss and fractures remains controversial.40,41
Psychiatric and cognitive dysfunction is present in 
70%–85% of patients with Cushing’s syndrome. Depression, 
emotional lability, and irritability are the most common 
manifestations; acute psychosis, mania, anxiety, panic 
attacks, suicidal ideation, and paranoia are rarer.42–45 
Hypercortisolemia is also associated with a decrease in 
brain volume, particularly the hippocampus, and related 
impairment in learning and short-term memory.46,47 Although 
psychiatric and cognitive symptoms improve after remission, 
many symptoms may persist.45,46
Excess glucocorticoids have a catabolic effect on skel-
etal muscles, skin, and connective tissue. Increased protein 
wasting and type II muscle-fiber atrophy is associated with 
significant muscle weakness, with predominant involvement 
of the pelvic girdle musculature.48,49 Vertebral fractures, back 
pain, and depression further lead to decreased mobility and 
disuse muscle atrophy. A persistently impaired quality of 
life, primarily of the physical domain, and persistent muscle 
weakness have been documented even several years after 
remission.50–53
Dyslipidemia (increased low-density lipoprotein, 
decreased high-density lipoprotein) and glucose intolerance 
occur in 45%–70% of patients.54–56 This reported prevalence 
Table 1 Clinical features of Cushing’s syndrome
Signs/symptoms Prevalence (%)
General
 Obesity or weight gain 70–95
 Rounded face (moon face) 81–90
 Supraclavicular/dorsocervical fat pads (buffalo hump) 50
Skin
 Hirsutism/alopecia 75
 Facial plethora 70–90
 violaceous striae 44–50
 Acne 20–35
 Easy bruising 35–65
Gonads
 Menstrual irregularity 70–80
 Decreased libido 24–80
Neuropsychiatric 70–85
 Emotional lability/depression
 Psychosis/mania
 Cognitive dysfunction/short-term memory loss
Musculoskeletal
 Muscle weakness/atrophy 60–82
 Osteopenia or fractures 40–70
 Decreased linear growth in children 70–80
Metabolic
 Hypertension 70–85
 Glucose intolerance 45–70
 Hyperlipidemia 70
 Hepatic steatosis 20
 Nephrolithiasis 21–50
Notes: Data from Storr et al,28 Faggiano et al,30 ilias et al,24 Pecori Giraldi et al,29 
Ross et al,147 Yanovski and Cutler,148 weber et al149 and Soffer et al.150
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of glucose intolerance is likely an underestimate, as many 
patients with normal fasting glucose have underlying glucose 
intolerance, and not all patients with Cushing’s syndrome 
undergo glucose-tolerance testing. Hypertension (cortisol-
mediated enhancement of vascular reactivity to vasoconstric-
tors and the mineralocorticoid effects of cortisol), though 
not invariably present, is frequently seen in patients with 
Cushing’s syndrome, with a prevalence of approximately 
80%.35,55 Hepatic steatosis and increased visceral adipose 
tissue are common in patients with Cushing’s syndrome.57,58 
These features of metabolic syndrome, along with a hyperco-
agulable state,59 lead to an increased cardiovascular risk that 
may not return to baseline after successful treatment.60–62
Diagnosis of Cushing’s syndrome
Clinical suspicion in patients with multiple and progressive 
signs and symptoms suggestive of Cushing’s syndrome 
should provoke diagnostic testing. Screening may be consid-
ered in patients with other features of Cushing’s syndrome, 
particularly with poorly controlled diabetes or hypertension, 
or unexplained osteoporosis. Patients with an incidentally 
discovered adrenal mass should be evaluated.
It is important to differentiate between the pathological 
hypercortisolemia of endogenous Cushing’s syndrome and 
that associated with pregnancy, glucocorticoid resistance, and 
pseudo-Cushing’s states like alcoholism, depression, severe 
obesity, anorexia nervosa, and bulimia. The hypercortisolism 
of pseudo-Cushing’s states is thought to be mediated via 
increased hypothalamic secretion of CRH. In contrast, hypo-
thalamic CRH is suppressed in true Cushing’s syndrome.
Biochemical tests in Cushing’s syndrome are based on the 
cardinal features of increased endogenous secretion of corti-
sol, loss of normal feedback of the hypothalamic–pituitary–
adrenal axis, and loss of the normal cortisol circadian rhythm. 
According to the 2008 Endocrine Society guidelines, the 
following tests should be used for the diagnosis of Cushing’s 
syndrome: 24-hour urinary free cortisol (UFC), late-night sal-
ivary cortisol, and/or a low-dose dexamethasone-suppression 
test (DST; 1 mg overnight or 2 mg/day over 48 hours).19 
None of these tests has 100% diagnostic accuracy; each test 
has its own caveats, and multiple tests are usually needed to 
establish the diagnosis (Table 2).1,19,31,63
UFC is an index of circulating free (biologically active) 
cortisol. Unlike plasma cortisol, which measures total cor-
tisol (bound and unbound), UFC results are not affected by 
factors that modulate the levels of corticosteroid-binding 
globulin (CBG). Inappropriate urine collection, increased 
fluid intake, and abnormal renal function can be associated 
with false-positive and -negative results.19,31,63 Review of 
urine volume and creatinine excretion can help assess the 
adequacy of urine collection. UFC values in Cushing’s syn-
drome are variable.64,65 Cushing’s syndrome is highly unlikely 
in the setting of three or more normal UFC levels, except in 
rare cases of cyclic Cushing’s syndrome. Values more than 
Table 2 Sensitivity, specificity, and caveats of screening tests for Cushing’s syndrome
Test Criteria Sensitivity Specificity Caveat (unreliable in)
UFC .3× ULN 80%–98% 45%–98% improper collection 
High fluid intake 
Renal insufficiency
Late-night salivary  
cortisol
.145 ng/dL 92%–100% 93%–100% improper collection/storage 
Licorice/chewing tobacco 
Smoking 
Aggressive tooth brushing
MN serum cortisol .7.5 μg/dL (awake) 
.1.8 μg/dL (sleeping)
91%–98% 
100%
92%–100% 
30%–62%
Patient not resting/sleeping 
Not drawn from indwelling line
1 mg Overnight DST Post-Dex F 
.1.8 μg/dL 
.5 μg/dL
91%–97% 
85%–90%
80%–94% 
95%–99%
Estrogen/mitotane (↑ CBG) 
Nephrotic syndrome/cirrhosis (↓ CBG) 
↓ Dex metabolism/clearance (cimetidine, fluoxetine, 
diltiazem, renal insufficiency) 
↑ Dex metabolism (phenytoin, rifampin, carbamazepine)
2-Day low-dose DST Post-Dex F 
.1.8 μg/dL
91%–98% 70%–95% Similar to 1 mg DST
Dex-CRH Post-CRH F 
.1.4 μg/dL
98%–100% 60%–100% Similar to DST 
Noncompliance with time points
Notes: To convert plasma cortisol from μg/dL to nmol/L, multiply by 27.6. To convert salivary cortisol from ng/dL to nmol/L, multiply by 0.028. Data from Newell-
Price et al,1,31 Nieman et al19 and de Castro and Moreira.63
Abbreviations: CBG, corticosteroid-binding globulin; Dex, Dexamethasone; CRH, corticotropin-releasing hormone; DST, Dex-suppression test; F, cortisol; MN, midnight; 
ULN, upper limit of normal; UFC, 24-hour urine free cortisol.
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three- to fourfold the upper limit of normal are generally 
diagnostic of Cushing’s syndrome.1,19,31
DSTs rely on the loss of glucocorticoid negative-feedback 
inhibition of CRH and ACTH secretion. In the overnight test, 
1 mg of dexamethasone is given at 11 pm, followed by mea-
surement of fasting plasma cortisol between 8 and 9 am the 
next morning. In the 2-day test, 0.5 mg of dexamethasone is 
given every 6 hours (starting at 9 am) for 2 days, with cortisol 
measurement at the beginning and end of the test. A cortisol 
level of #1.8 μg/dL (50 nmol/L) at the end of either test 
excludes Cushing’s syndrome (Table 2).19 Variable absorption 
and metabolism of dexamethasone can affect the results of the 
DSTs. Estrogen treatment and pregnancy can increase CBG 
levels, leading to false-positive DST results. For accurate 
results, estrogen treatment should be stopped for 4–6 weeks to 
allow CBG levels to return to baseline.1,19 Some (3%–8%) CD 
patients show suppression of cortisol levels below 1.8 μg/dL 
(50 nmol/L) on DST.1,66 Multiple repeated tests may be needed 
to establish the diagnosis in these cases.
Salivary cortisol, like UFC, measures free cortisol, and is 
therefore not affected by CBG levels. Diagnostic ranges vary 
between studies, due to the different assays and comparison 
groups used to set cutoff points.63 Salivary cortisol can be 
measured by immunoassay or liquid chromatography–tandem 
mass spectrometry (LC/MS-MS). Given the lower sensitivity 
of LC/MS-MS (as it may not measure cortisol metabolites/
precursors), immunoassay remains the preferred methodol-
ogy for screening of Cushing’s syndrome.67–69 Educating 
the patient on optimal timing of specimen collection while 
taking into account their normal sleep–wake cycle, as well as 
avoiding exciting or stressful experiences on the evening of 
the test, are important for an accurate salivary cortisol result. 
False-positive results can also be seen, due to contamination 
of the saliva sample with widely available nonprescription 
topical hydrocortisone creams and ointments. However, 
overall, ease of collection, stability at room temperature, 
and a greater than 90% sensitivity and specificity make it 
a highly useful test, especially in outpatients, children, and 
in assessment of cyclic Cushing’s syndrome.67–69 Midnight 
plasma cortisol levels also can be used for screening. A single 
sleeping midnight plasma cortisol level of less than 1.8 μg/dL 
(50 nmol/L) excludes active Cushing’s syndrome.70 A mid-
night plasma cortisol level, drawn while the patient is resting 
but not fully asleep, of more than 7.5 μg/dL (207 nmol/L) is 
a more specific cutoff, but can miss up to 7% cases of mild 
Cushing’s syndrome.71,72
If the diagnosis remains unclear, dexamethasone-
suppressed CRH stimulation (Dex-CRH) test73,74 or the 
desmopressin test75,76 can be performed to distinguish further 
between CD and pseudo-Cushing’s states. However, the 
exact diagnostic accuracy of these tests and the optimal 
cutoffs for diagnosis need further evaluation.77 Moreover, 
similarly to other dexamethasone tests, variable absorp-
tion and metabolism of dexamethasone, especially in the 
setting of concomitant use of other commonly prescribed 
medications, can affect the accuracy of the test.78 Recently, 
a prospective study of 73 patients with clinical features 
of hypercortisolism and an abnormal DST or UFC result 
reported a positive predictive value of 100% and a negative 
predictive value of 90% for the Dex-CRH test (sensitivity 
94%, specificity 100%) using a 15-minute post-CRH cortisol 
cutoff of 3.2 μg/dL (87 nmol/L).79
Establishing the cause  
of Cushing’s syndrome
Once the diagnosis of Cushing’s syndrome has been estab-
lished, the next step is to differentiate between the three 
causes. Measurement of plasma ACTH levels is the initial 
step in the differential diagnosis. A two-site immunoradio-
metric assay is preferred over radioimmunoassay, because 
it better discriminates low or suppressed ACTH levels.80 
To avoid falsely low results, ACTH levels should be mea-
sured on multiple occasions, and samples should be col-
lected in prechilled ethylenediaminetetraacetic acid tubes, 
transported in an ice bath, and processed immediately.1 
Values ,5 pg/mL (1.1 pmol/L) suggest ACTH-independent 
Cushing’s syndrome. Imaging studies of the adrenal gland 
can then identify unilateral or bilateral lesions. The glands 
may appear normal in primary pigmented nodular adrenal 
disease. Patients with proven ACTH-independent hypercor-
tisolism but normal adrenal imaging studies should undergo 
screening for exogenous glucocorticoids, assessment for 
other features of Carney’s complex, and possibly genetic 
testing for PRKAR1A mutations.81 A paradoxical increase 
in glucocorticoid excretion in response to dexamethasone 
during the Liddle test (0.5 mg dexamethasone every 6 hours 
for 48 hours, followed by 2 mg every 6 hours for 48 hours) 
can further help identify patients with primary pigmented 
nodular adrenocortical disease.82 Recently, an inactivating 
germ-line mutation of ARMC5, a putative tumor-suppressor 
gene, has been implicated in the development of primary 
bilateral macronodular hyperplasia.83–85 Patients with this 
mutation show familial clustering and bilateral disease, and 
often present with a more severe clinical phenotype. Genetic 
testing for this mutation may help in earlier diagnosis and 
better management of these cases.85
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An inappropriately normal or elevated ACTH level 
(.20 pg/ml, 4.4 pmol/L) is consistent with an ACTH-
dependent form of Cushing’s syndrome. Patients with mild 
adrenal Cushing’s may not have suppressed ACTH levels. 
Moreover, recently, intra-adrenal production of ACTH has 
been reported in macronodular adrenal hyperplasia, although 
peripheral ACTH levels were suppressed.26 CRH stimulation 
and high-dose DSTs may help differentiate between adrenal 
and ACTH-dependent forms of Cushing’s syndrome when 
ACTH results are indeterminate.1
Although there is significant overlap in ACTH levels 
between CD and EAS, extremely high levels (.500 pg/mL, 
110 pmol/L) usually reflect EAS.1,31 Sex may help: 90% of 
cases of ACTH-dependent Cushing’s syndrome in women 
are caused by CD.
A pituitary MRI should be obtained in ACTH-dependent 
cases. A large mass (.6 mm) strongly suggests CD. 
However, ACTH-secreting pituitary tumors are usually small 
and may not be detected, even with newer, more advanced 
MRI techniques (spoiled gradient-recalled acquisition or 
dynamic MRI sequences) in 20%–58% of patients with 
CD.86,87 Moreover, ∼10% of “healthy” individuals can have 
incidental pituitary lesions up to 6 mm in size.88 Differential 
diagnosis of ACTH-dependent Cushing’s syndrome can 
therefore be very challenging.
The high-dose DST (2 mg given every 6 hours for 
48 hours, or the overnight test with a single 8 mg dose) is 
based on the concept that corticotrope adenomas arise clon-
ally from normal cells and retain some sensitivity to gluco-
corticoid negative feedback, while ectopic ACTH-secreting 
tumors do not. In the overnight test, a greater than 69% sup-
pression of cortisol levels following 8 mg of dexamethasone 
suggests a pituitary source of ACTH.89 Logistic regression 
modeling has shown that the diagnostic accuracy of this test 
is less than the pretest likelihood based on clinical features 
alone.90 Due to the poor diagnostic accuracy (∼80%) of a 
high-dose DST, many endocrinologists do not recommend 
performing the test unless inferior petrosal sinus sampling 
(IPSS) is not available.1,91
In the CRH-stimulation test, recombinant ovine or human 
sequence CRH (1 μg/kg, maximum 100 μg dose) is used to 
stimulate corticotrope tumors to secrete ACTH. Most patients 
with CD respond with an increase in ACTH (.34%) and/or 
cortisol (.20%) levels within 45 minutes of intravenous 
administration of ovine CRH (sensitivity 93%).92 Following 
administration of human CRH, most CD patients have at least 
a 14% increase in cortisol levels (sensitivity 85%, specificity 
100%).93 While some reports have shown ovine CRH to be 
superior to recombinant human CRH,94 others have found 
similar responses.95 A systematic review of all published 
series on the CRH-stimulation test revealed that 7%–14% 
of patients with CD fail to respond to CRH.31 Some patients 
with ACTH-secreting pulmonary carcinoids (∼10%) can 
respond to dexamethasone and/or CRH.24
If the CRH-stimulation test and high-dose DST are both 
consistent with a pituitary source and imaging studies identify 
a pituitary lesion consistent with an adenoma (.6 mm), no 
further testing is necessary. On the other hand, if biochemical 
testing is discordant and/or the pituitary MRI is normal or 
equivocal (lesion ,6 mm), IPSS with ACTH measurements 
before and after CRH administration should be performed.1,96 
A central-to-peripheral ACTH gradient of $2.0 before 
and/or $3.0 after CRH administration is consistent with 
CD. A systematic review of all published studies on IPSS 
showed an overall sensitivity of 96% and specificity of 100% 
using these criteria.31
Although IPSS is the gold-standard test to distinguish 
between a pituitary and ectopic source of ACTH, it is an 
invasive procedure requiring a high degree of skill, and thus 
is best performed in experienced centers. False-negative IPSS 
results of 1%–10% have been attributed to anomalous venous 
drainage, abnormal venous anatomy, lack of expertise, and 
technical problems.97–99 Review of the IPSS venogram and/or 
prolactin measurement during IPSS can improve diagnostic 
accuracy and decrease false-negative results.100–102 A baseline 
prolactin inferior petrosal sinus to peripheral (IPS/P) ratio 
(ipsilateral to the dominant post-CRH ACTH IPS/P ratio) of 
1.8 or more suggests successful catheterization during IPSS. 
Prolactin-normalized ACTH IPS/P ratios can then be used 
to differentiate between a pituitary and ectopic source of 
ACTH. Values #0.7 suggest EAS, and those $1.3 suggest 
CD. Indeterminate values (0.7–1.3) need further study.102 
False-positive IPSS results can occur in rare cases of ectopic 
CRH production103,104 and in patients with cyclic Cushing’s 
syndrome if the normal corticotropes are not completely 
suppressed.102 Documentation of sustained hypercortisolism 
prior to dynamic testing therefore remains crucial.
Localization of the source of ACTH
Cushing’s disease
As discussed earlier, advanced MRI techniques often do not 
identify pituitary adenomas. While IPSS localizes the tumor 
to the pituitary gland, its role in determining the precise tumor 
location remains controversial. Using an intersinus ratio of 
1.4 or more before or after CRH to predict the location of 
pituitary adenomas,105 a review of 19 studies (313 cases) 
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reported poor localizing accuracy (78% overall, 50%–100% 
in individual studies).31 More recently, Wind et al found that 
IPSS correctly predicted tumor location in 273 of 396 patients 
(positive predictive value 69%) with surgically proven CD 
and a lateral adenoma.87 Mulligan et al demonstrated that 
the use of prolactin-normalized ACTH intersinus ratios 
led to improvement in the lateralization accuracy of IPSS 
(75% versus 54%) in 28 patients with surgically proven CD.106 
Although these data are promising, larger prospective studies 
are needed. Therefore, at present IPSS lateralization results 
can only be used as a guide for where to begin initial trans-
sphenoidal exploration in MRI negative cases. A thorough 
exploration of the pituitary gland is essential before using 
lateralization results for hemihypophysectomy.
Ectopic ACTH syndrome
Structural (CT and MRI) and functional (somatostatin scin-
tigraphy and positron emission tomography [PET] scans) 
imaging studies are used to identify the source of ACTH 
in EAS, but the optimal imaging strategy has not been well 
defined. Since no single imaging modality identifies all 
tumors, correlation of multiple studies is needed.24,107
Because the majority of these tumors are intrathoracic, 
initial imaging should focus on the chest, with additional 
studies obtained as needed. Thin-cut multislice CT scans 
and 3 T MRI improve tumor detection, but also can give 
false-positive results.107 As many NETs express somatostatin-
subtype (sst) receptors, they may be detected via somatostatin 
scintigraphy (eg, octreotide scan). The ability of these scans 
to identify a tumor depends on the type (sst1–5) and degree 
of sst-receptor expression, size of the tumor, and the dose 
(6–18 mCi pentetreotide) of the radiopharmaceutical and 
the use of single photon emission CT.108 In vitro studies have 
shown that glucocorticoids downregulate sst-receptor expres-
sion in human neuroendocrine cells.109 This has been described 
in vivo, as well in two patients with ACTH-secreting pulmo-
nary NETs, where mifepristone (a glucocorticoid receptor 
antagonist) treatment led to a change in the octreotide-scan 
status and correct localization of the tumor.110 This phenom-
enon of improved diagnostic ability of the octreotide scan 
after medical control of hypercortisolism needs to be further 
evaluated in larger studies. Ga68-DOTATATE and DOTATOC, 
PET radiopharmaceuticals with high affinity for sst2, have 
shown promise in identifying gastrointestinal–pancreatic and 
pulmonary NETs. However, patients with ACTH-secreting 
tumors were not included.111–113 The use of 68Ga-DOTATATE 
PET scans in identifying the source of ACTH in ectopic Cush-
ing’s syndrome needs further investigation.
As most EAS tumors are slow growing and have low 
metabolic activity, fluorodeoxyglucose (18F) PET scans 
have limited utility in tumor localization; they may help 
define the extent of metastatic disease.114 Radiolabeled l-3,4- 
dihydroxyphenylalanine and (11C) 5-hydroxytryptamine PET 
scans can help with localization.107,115,116 Non-IPSS venous 
sampling usually does not provide any additional information, 
and is not considered necessary in the evaluation of ectopic 
Cushing’s syndrome.24,117
Management
Surgery
Surgical resection of the source of glucocorticoid excess 
(pituitary adenoma, nonpituitary tumor-secreting ACTH 
or adrenal tumor[s]) remains the first-line treatment of 
all forms of Cushing’s syndrome. The initial remission 
rate after transsphenoidal surgery is 60%–80% (,15% in 
macroadenomas),118 with a relapse rate of up to 20% within 
10 years.1,119,120 However, the success rate depends on the skill 
and experience of the neurosurgeon, and can be as high as 
90% at experienced centers. Patients with hypocortisolism 
in the immediate postoperative period need glucocorticoid 
replacement until the recovery of the hypothalamic–pituitary–
adrenal axis (usually 6–18 months after surgery).1 Although 
long-term remission is more likely when postoperative cor-
tisol levels are less than 2 μg/dL (,54 nmol/L), no cortisol 
value excludes the possibility of recurrence.120 These data 
emphasize the need for ongoing surveillance and alternative 
treatment modalities for CD.
As in CD, surgical removal of an ectopic ACTH-
secreting tumor is the optimal treatment. However, occult 
or metastatic tumors require medical therapy or bilateral 
adrenalectomy.24
Laparoscopic unilateral or bilateral adrenalectomy is the 
treatment of choice in adrenal causes of Cushing’s syndrome, 
and has an excellent prognosis in benign cases.121 Bilateral 
adrenalectomy in ACTH-dependent Cushing’s syndrome may 
be used when surgery and medical therapy are unsuccessful, 
or based on patient preference. It leads to rapid resolution of 
hypercortisolemia and related morbidity.122 However, after 
bilateral adrenalectomy, patients need lifelong glucocorticoid 
and mineralocorticoid replacement. Another concern with 
bilateral adrenalectomy in patients with CD is the development 
of Nelson’s syndrome (local tumor growth with mass effects 
and increased ACTH levels causing hyperpigmentation). 
Modern imaging techniques allow early detection and man-
agement of corticotrope tumor progression after bilateral 
adrenalectomy in these patients.123 Some physicians advocate 
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prophylactic pituitary radiotherapy to decrease the risk of 
development of Nelson’s syndrome.124
Pituitary radiotherapy
Persistent hypercortisolemia after transsphenoidal surgery due 
to residual tumor can be treated with radiotherapy. Adjunctive 
medical control of hypercortisolemia may be needed 
while awaiting the effects of radiotherapy. Conventional 
fractionated radiotherapy is very effective, but its effects 
may be delayed up to 10 years, and it can be associated with 
long-term hypopituitarism.125 Stereotactic radiosurgery is 
more rapidly effective, but has been associated with a relapse 
rate of 20%.126
Medical therapy
Medical control of hypercortisolemia may be needed in 
occult cases, while awaiting surgery, when surgery is con-
traindicated or unsuccessful, and while awaiting the effect of 
radiation treatment. Medical treatments for hypercortisolemia 
include agents that inhibit steroidogenesis (ketoconazole, 
metyrapone, mitotane, and etomidate), modulate ACTH 
release (somatostatin and dopamine agonists) or block 
glucocorticoid action at its receptor (mifepristone) (Table 3).127 
A major concern with all medical therapies is the risk of 
overtreatment and adrenal insufficiency. Medical control 
of hypercortisolemia can be achieved in two ways: either 
by blocking cortisol production to achieve normal levels, 
or by blocking cortisol secretion completely along with 
glucocorticoid replacement (block and replace). Regardless 
of the strategy, all patients on medical therapy should be 
educated about the symptoms of adrenal insufficiency and 
the emergency use of glucocorticoids.
Ketoconazole, a steroidogenesis inhibitor, has a rapid 
onset of action. It inhibits the first step in cortisol biosynthesis 
(side-chain cleavage) and to a lesser degree 11β-hydroxylase 
and 17,20-desmolase.128 It requires an acidic environment for 
maximal absorption, and thus has reduced efficacy if used in 
combination with proton-pump inhibitors. Although used off-
label, ketoconazole is usually the first-line agent for medical 
control of hypercortisolism in the US. However, gastrointes-
tinal side effects, hepatocellular dysfunction, gynecomastia, 
and decreased libido in men may limit its use.129,130 The 
European Medicines Agency (EMA) has recently withdrawn 
ketoconazole from the market because of hepatic dyscrasia 
in patients treated for fungal infections.131 A similar safety 
announcement from the US Food and Drug Administration 
Table 3 Drugs used to treat Cushing’s syndrome: mechanism of action, dosage, and important side effects and concerns
Drug Mechanism of action Dose Side effects/concerns
Steroidogenesis inhibitors
 Ketoconazole inhibits CYP11A1 and  
CYP11B1, other enzymes  
to lesser extent
400–1,600 mg/day Hepatotoxicity, Gi discomfort, decreased testosterone levels, 
gynecomastia, adrenal insufficiency; needs gastric acidity for 
bioavailability
 Metyrapone inhibits CYP11B1 500–4,500 mg/day Dizziness, rash, Gi discomfort, acne and hirsutism in women, 
worsening or new hypertension and hypokalemia, adrenal 
insufficiency, neutropenia (rarely)
 Mitotane Adrenolytic, inhibits  
CYP11A1 and CYP11B1,  
other possible actions
2–5 g/day Hepatotoxicity, Gi discomfort, hypercholesterolemia, 
gynecomastia, prolonged bleeding time, dizziness, ataxia, dysarthria, 
memory loss, adrenal insufficiency; teratogenic, increases CBG
 Etomidate inhibits CYP11A1 and  
CYP11B1
0.03–0.3 mg/kg/h Nephrotoxicity (propylene glycol toxicity), sedation at higher doses, 
adrenal insufficiency; needs to be initiated in intensive care setting
Tumor-specific therapy
 Pasireotide Somatostatin analog  
(sst5, also sst1–3)
750–2,400 μg/day Hyperglycemia, Gi discomfort, cholestasis, growth-hormone 
deficiency
 Cabergoline Dopamine agonist (D2R) 0.5–7 mg/week Headache, dizziness, GI discomfort, cardiac valve fibrosis at high doses
Glucocorticoid-receptor antagonist
 Mifepristone Reversible blockade of  
glucocorticoid receptor,  
antiprogestin
300–1,200 mg/day Hypokalemia, worsening hypertension, adrenal insufficiency, 
endometrial hyperplasia, Gi discomfort; cortisol levels cannot be 
used to titrate therapy
Other potential agents
 Retinoic acid inhibits POMC transcription  
and ACTH secretion
10–80 mg/day Conjunctival irritation, nausea, arthralgias, headache
 LCi699 inhibits CYP11B1 4–100 mg/day Fatigue, nausea, diarrhea, headache, adrenal insufficiency
 Gefitinib Tyrosine-kinase inhibitor  
that targets EGFR
Rash, pruritus, Gi discomfort, peripheral edema; only in vitro and 
animal data available, has not been tested in humans
Abbreviations: ACTH, adrenocorticotropic hormone; CBG, corticosteroid-binding globulin; CYP, cytochrome P450; CYP11A1, cholesterol side-chain cleavage 
enzyme; CYP11B1, 11β-hydroxylase; D2R, dopamine receptor subtype 2; EGFR, epidermal growth factor receptor; Gi, gastrointestinal; POMC, proopiomelanocortin; 
sst, somatostatin-receptor subtype.
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(FDA) advised against its use for any fungal infection.132 When 
used for the control of hypercortisolemia, liver-function tests 
need to be monitored closely. Despite the risks associated, 
ketoconazole remains an important drug in the physician’s 
armamentarium for medical control of hypercortisolism. The 
EMA has therefore invited national authorities with expertise 
in this area to make ketoconazole available for patients with 
Cushing’s syndrome under controlled conditions.131
Metyrapone inhibits 11β-hydroxylase and has a rapid onset 
of action. In the US, it is primarily used as adjunctive therapy 
with other steroidogenesis inhibitors and with radiation therapy 
in CD.133,134 Increased deoxycorticosterone levels, due to 
inhibition of 11β-hydroxylase by metyrapone, can lead to salt 
retention and (rarely) hypertension, while increased adrenal 
androgens can lead to new or worsening hirsutism and acne in 
women. Both ketoconazole and metyrapone have been associ-
ated with an increase in ACTH secretion and loss of control of 
hypercortisolism over time in CD (escape phenomena).
Mitotane, another steroidogenesis inhibitor, is also 
adrenolytic. It has a slow-onset, long-lasting action. Mitotane 
increases CBG levels, leading to falsely high total cortisol 
levels, complicating titration of therapy. It is teratogenic, not 
well tolerated, and is primarily used in the treatment of adreno-
cortical carcinoma.135 During treatment, plasma mitotane con-
centrations must be monitored.135 Etomidate is a substituted 
imidazole anesthetic agent that inhibits 11β-hydroxylase. It 
has been used for rapid control of hypercortisolemia in hos-
pitalized patients in an intensive care unit setting, and is the 
only available intravenous parenteral agent.136
Recently, somatostatin (sst5 and sst2) and dopamine (D
2
) 
receptors have been identified as therapeutic targets in CD.137 
Pituitary-directed therapy with pasireotide (a somatostatin 
analog with high affinity for sst1, -2, -3, and -5) or cabergoline 
(a dopamine agonist) normalizes UFC in 20%–40% of patients 
with CD.138,139 This represents an off-label use for cabergoline. 
Pasireotide (Signifor), the first agent approved by the EMA 
and FDA for the treatment of patients who have failed surgery 
or are not surgical candidates, is most effective when UFC 
is less than twice the upper limit of normal. Seventy-three 
percent of patients treated with pasireotide develop glucose 
intolerance138 due to inhibition of incretin secretion, with a 
concomitant decrease in insulin secretion. Glucagon-like 
peptide-1 agonists or dipeptidyl peptidase-4 inhibitors can 
effectively control glucose levels in this setting.140
Mifepristone (RU-486, Korlym), a glucocorticoid and 
progesterone-receptor antagonist, has been approved in the US 
for control of hyperglycemia secondary to hypercortisolism 
in patients with Cushing’s syndrome who have failed surgery 
or are not surgical candidates. It has a rapid onset of action, 
and can be used to treat acute complications of Cushing’s syn-
drome, especially cortisol-induced psychosis.141,142 It is impor-
tant to note that cortisol and ACTH levels remain unchanged 
or increase with the use of mifepristone, and cannot be used to 
gauge treatment success or to diagnose adrenal insufficiency. 
Moreover, increases in ACTH and cortisol levels can lead 
to (worsening of) mineralocorticoid effects (hypertension, 
edema, hypokalemia), and women can develop endometrial 
thickening during prolonged treatment.141,142
Other agents currently under (preclinical) study for 
the medical control of hypercortisolemia include LCI699 
(an 11β-hydroxylase inhibitor), retinoic acid, and gefitinib 
(tyrosine-kinase inhibitor with EGFR [epidermal growth 
factor receptor] as target) (Table 3).143–145
Combination therapy with different agents may be 
needed to achieve normal plasma cortisol levels in patients 
with moderate-to-severe hypercortisolism. This can reduce 
drug-related adverse events if lower combined doses are 
effective. A small study of 17 patients showed an overall 
response rate of 88% after sequential addition of ketocon-
azole and/or cabergoline when initial pasireotide therapy was 
not successful.146 Overall, medical treatment in Cushing’s 
syndrome needs to be individualized according to patient 
characteristics, potential side effects, and other pharmaco-
logical properties of the drugs.127
Conclusion
Cushing’s syndrome, a rare disorder, is associated with signifi-
cant morbidity and mortality. Clinical presentation can be broad, 
and establishing the diagnosis can be difficult. Early recognition 
and rapid control of hypercortisolemia is necessary to decrease 
morbidity and mortality in these patients. Surgery remains 
the optimal treatment in all forms of Cushing’s syndrome, but 
may not be curative. Individualized medical treatment and a 
multidisciplinary approach are needed for optimal control of 
hypercortisolemia and management of comorbidities. New 
alternative modalities of medical treatment are needed.
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